InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,367.92
(
0.13%
)
US TECH 100
18,677.20
(
0.45%
)
Dow Jones
38,734.83
(
-0.34%
)
Brent Oil
81.69
(
-0.11%
)
Bitcoin
67,147.39
(
-3.40%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

$heff

Send PM Follow Ignore
Followers 3421
Posts 32269
Boards Moderated 1
Alias Born 07/08/2006

$heff

Re: $heff post# 90083

Tuesday, 09/22/2015 3:49:35 PM

Tuesday, September 22, 2015 3:49:35 PM

Post# of 97237
$MSTX..DD post.. Ritu Baral from Cowen & Co. Maintains Outperform on Mast Therapeutics Inc Ahead of Sickle Cell Crisis EPIC Data in 1Q:16 Target $3

$MSTX Canaccord $3 PT Enrollment has now reached >70% of the planned n=388 patients, "expects the results to be positive" Q1 2016

Canaccord Reiterates Buy on Mast Therapeutics Inc Ahead of Top-line Phase 3 Sickle Cell Data http://t.co/7ETSwCchgV $MSTX

@SmarterAnalyst: $MSTX Roth Capital Reiterates Buy on Mast Therapeutics Inc Following 2Q:15 Update http://t.co/Hp5gWlY5lg

@BlinkX90: $MSTX Starting to find MST-118 patient experiences being expressed on sickle cell group sites. (found this (cont) http://t.co/Co1YukC674t

Sheff's Station...All Aboard...Sign Up Here!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up